BGLAF (BioGaia AB) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BGLAF BioGaia AB BGLAF
100 GF Score
Price $12.20
GF Value $12.55
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioGaia AB Net Loan?

Net Loan only applies to banks and insurance companies.

BGLAF
100GF Score
BioGaia AB BGLAF
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioGaia AB (BGLAF) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of $12.20 is trading 2.8% below its estimated GF Value™ of $12.55. GuruFocus considers BioGaia AB to be Fairly Valued.

Key valuation signals for BGLAF:

  • Net Loan:
  • GF Value™: $12.55 vs. price of $12.20 (2.8% below fair value)
  • GF Score™: 100/100 with 2 warning signs

No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for BGLAF

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.20
Price
$12.55
GF Value